192 results about "Cannabis substance" patented technology

A cartridge handling machine for vape type cartridges is provided, which may comprise a filling module for filling of cartridge bodies with viscous consumable fluids, particularly oils extracted from hemp and cannabis and compositions thereof. The cartridge handling machine may also comprise a capping module to provide for synchronized filling of the filled cartridges and capping the cartridges with a cap, such as a mouthpiece or other cap device developed for such cartridges. The individual filling and capping modules can be operated independent of each other such that the cartridge handling machine preferably comprises both a filling module and capping module that preferably are integrated together for synchronized operation, although these modules may also be constructed and operated as separate machines for the respective filling and capping of these types of vape cartridges.

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking immunosuppressant drugs. In particular the immunosuppressant drug is a calcineurin inhibitor. More particularly the immunosuppressant drug is tacrolimus. Where the CBD is used in combination with an immunosuppressant drug, caution should be taken. For example, the dose of either the CBD and / or the immunosuppressant drug may be required to be reduced. Moreover, the patient may need to be monitored for side effects of said drug-drug interaction. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

The system and techniques disclosed herein perform advanced and automatic age verification. The age verification system (AVS) is designed for automated and accurate age-restricted access control and age verification for the sale of age-controlled products. For example, the AVS can be employed to perform age-verification to permit the legal sale / purchase of age-controlled products such as alcohol, tobacco, cannabis, and the like, and Also, the AVS can be used to control legal access to age-restricted areas such as casinos, movie theaters, bars, and the like. The AVS can include a scanner for scanning a barcode printed on an identification (ID) card, an application, and a computer unit having output devices for generating visual, audible, and electronic signals to view, alert, and control age-restricted entry and control the sale of age-controlled products. The AVS can include automatic door lock functionality that supports age-restricted access control.

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C6 (CBD-C6), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the cannabinoid can be produced by synthetic means and a method for the production of CBD-C6 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C6 in models of disease.

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis / marijuana, nicotine, and activities including gambling.Compounds are of general formulawith substituents as defined herein.

The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD ap-pears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocan-nabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

Vaporizer pods for use with a vaporizer configured to generate vapor from dry herbs, and the vaporizer pods comprising reconstituted tobacco and very low THC reconstituted cannabis.

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C1 (CBD-C1), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the 5 cannabinoid can be produced by synthetic means and a method for the production of CBD-C1 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C1 in models of disease.

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigero (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C6 (CBD-C6), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the cannabinoid can be produced by synthetic means and a method for the production of CBD-C6 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C6 in models of disease.

The present disclosure relates to a filter for a smoking device, such as, but not limited to, a water pipe, or a cigarette, such as, but not limited to, a cannabis cigarette. The filter includes a body that is positionable over a mouthpiece of the smoking device, to filter impurities from smoke drawn therethrough, and a base that secures the body over the mouthpiece such that smoke is drawn therethrough, prior to inhalation by a user. The body can include one of more filtration layers, such as a first layer formed from a material selected to filter carcinogens and other impurities from the smoke prior to inhalation, and a second layer formed from a material selected to minimize or prevent the transmission of bacteria, viruses, or other contagions from a user's mouth to the smoking device. Each of the filtration layers can also be formed from one or more materials.

The present invention provides for a method for obtaining an oil extract of cannabis. The method includes: (a) contacting cannabis biomass and an edible oil; (b) pressing between a pair of plates to provide spent cannabis and an oil extract of cannabis; and (c) separating the spent cannabis biomass and the oil extract of cannabis.

The present disclosure concerns methods for reducing nicotine dependency, i.e. by reducing tobacco smoking and promoting tobacco smoking secession; and by reducing marijuana dependency, i.e. by reducing marijuana smoking and promoting marijuana smoking cessation. More particularly the present disclosure concerns formulations of cannabinoids for use in reducing nicotine and marijuana dependency and promoting tobacco and marijuana smoking secession.

A vaporizing device includes a main body with a chamber extending between first and second openings. A condensation cup at the bottom of the chamber collects moisture and unvaporized substances. A stem extends through the second opening, and a mouthpiece extends through the first opening. The mouthpiece is a tubular member with an open end and a plurality of outlet openings. Stoppers secure the mouthpiece and stem within the chamber. A magnetic tool may be provided for applying vaporizable substances. In use, a section of the stem is locally heated to vaporization temperature, a substance is applied to the heated section, and vapor is drawn through the mouthpiece. The condensation cup prevents residue from reaching the user, maintaining cleanliness and hygiene. The device supports tool-free disassembly and is suitable for tobacco, cannabis, herbal blends, and concentrates.

Aseptic product processing systems and methods may include a hopper for introducing the product into the system and one or more components through which the product flows as it is processed, an enclosure surrounding one or more of the components, a gassing assembly comprising a plurality of gassing elements to maintain a substantially constant flow of inert gas over the product as it travels through the system components, and a filtered gas recirculation system that recirculates air or filtered gas through the enclosure. Such systems may be particularly advantageous for use in the cannabis industry.

The disclosed technology includes cannabinoid oral products, and methods for making same. In some embodiments, the oral products are pouches including cannabinoid infused wafers. In some embodiments, the method of making the cannabinoid oral products includes preparing an emulsion, preparing a spray dry solution, spray drying solution into cannabinoid and carbohydrate particles, preparing a paste, preparing a wafer in a heated vacuum oven, fragmenting the wafer into cannabinoid infused wafer fragments, mixing the cannabinoid infused wafer fragments with starch, and dispensing the cannabinoid infused wafer fragments into pouches. The methods may also include labeling the oral products, for example, with a THC warning symbol.

Compositions including Δ-9-tetrahydrocannabinol (THC) and a carbonic andydrase inhibitor and methods of using these compositions for the treatment of obstructive sleep apnoea (OSA). The treatment method also includes administering dronabinol and acetazolaminde and combinations thereof to a subject in need thereof.

An infusion kit and a method for using said kit for infusing a base substance with an additive substance. The additive substance is deposited into a permeable container, which is itself inserted into a non-permeable container. The base substance is then added to the non-permeable container and the non-permeable container is heated to thereby infuse the base substance with the additive substance. In one embodiment, the additive substance is roasted in the permeable container before infusion begins. In some embodiments, a non-permeable casing encloses the permeable container during roasting. In a preferred embodiment, the non-permeable container is heated by immersion in a temperature-controlled liquid bath system, such as would be found in a sous-vide or similar system. However, many other heating systems may be used. The additive substance may be derived from a plant, including but not limited to cannabis.

A fluid dispenser for discharging a nicotine and / or cannabis-containing fluid as a replacement for tobacco products consumed by burning same, including a fluid store for storing the fluid before output, a mouthpiece for discharging the fluid, a connecting fluid channel and an outlet valve assembly, with which the fluid channel is opened and closed. The outlet valve assembly has an elastically deformable tube section forming part of the fluid channel, and an actuation surface is located on an outer side of the dispenser for actuating the outlet valve assembly. This actuation surface is coupled to a tube-shaping segment, with which the tube section is deformed from a state in which the fluid channel is closed into a state in which the fluid channel is open by applying force to the actuation surface, to thereby allow for the discharge of fluid.

Filters of conventional design consist of a small paper tube which is filled with activated carbon and is closed at both ends by cellulose fibres and / or ceramic caps. Filters consisting only of cellulose also exist. The filters are used to rotate them with cigarette paper to form a cigarette or a joint. In normal use, one of the filter ends can be singed or burned when the cigarette or the joint is smoked to the end. In addition, specifically in the case of cannabis, oils emerging as a result of heat can clog the cellulose, but in particular also the small air passages of ceramic caps. The invention is intended, by means of the thermal insulation, to prevent scorching and clogging of the filter elements. The filter elements consist of cellulose and carbon or consist of ceramic cap / carbon or only cellulose and are to be placed centrally in a small tube consisting of paper. The cavities between the filter elements and the end of the tube are to be filled with specially shaped inserts made of paper or ceramic. The extension of the filter on both sides by the small paper tube is intended to ensure thermal insulation and to prevent the embers from being in direct contact with the cellulose filter or with the ceramic cap. As a result of the enlarged area, the specially shaped inserts made of paper or ceramic are intended to prevent clogging by emerging oils. In addition, the inserts prevent tobacco or cannabis particles from being able to fall unhindered into the paper tube.

Compositions comprising 0.1-50 % delta-9-tetrahydrocannabinol and / or cannabidiol in forms suitable for continuous delivery and use thereof in the treatment of a variety of diseases and pathological disorders are disclosed. In preferred embodiments, the compositions are in a form suitable for delivery via a portable infusion pump or transdermal patch. The disorders to be treated include pain, cancer, seizure disorders, and Parkinson's disease. Depending on the disorder to be treated, the compositions may optionally further comprise additional active agents such as dopaminergic agents.

The present invention provides a novel room-temperature extraction system and method for cannabis and hemp, utilizing custom membrane filtration to efficiently isolate cannabinoids, terpenes, and other bioactive compounds while reducing energy consumption. This multi-stage system begins with a custom milling machine that preprocesses biomass by separating non-target components, such as cellulose-rich stalks, to improve extraction efficiency. The core extraction process employs a series of custom membranes designed to selectively filter cannabinoids and terpenes, minimizing impurities without the need for traditional sub-zero cooling. Each membrane stage incorporates solvent recovery to recycle ethanol, reducing waste and operational costs. In the final stage, a custom concentrator removes residual ethanol, decarboxylates THCa to THC, and crystallizes sugars to prevent downstream clogging. This room-temperature extraction system significantly enhances yield, purity, and sustainability, making it a scalable and cost-effective solution for cannabis and hemp processing industries, as well as applicable for pharmaceutical and nutraceutical uses.

Embodiments of the present disclosure generally relate to fire retardant compositions, fire retardant products, and methods for preparing such fire retardant compositions and products. A variety of fire retardant products may contain the fire retardant composition. The fire retardant product may be or include a dry fire retardant product, a wet, foam, or gel fire retardant product, and / or may include one or more base products (e.g., wood, paper, textile, fiber, hemp, cannabis, combinations thereof, or other products). In one or more embodiments, a fire retardant composition is provided and contains a product composition prepared from a mixture containing about 90 wt% to about 99.9 wt% of a polysaccharide-base composition and about 0.1 wt% to about 10 wt% of a bio-stimulant composition, or contains a reaction product of a weight ratio of the polysaccharide-base composition and the bio-stimulant composition in a range from about 50:1 to about 200:1.

The invention provides certain compositions and methods for dental care, which alone or in combination with other dental technologies can help to achieve better outcomes in terms of the enhancement of oral hygiene as regards to preservation of the healthy oral and / or dental flora, minimization or a reduction of the proportion of harmful bacteria, and further facilitate the enhancement of a more healthy appearance of teeth and gums. The oral formulation for improving oral and / or dental hygiene, and / or for enhancing the healthy appearance of teeth and gums, comprises Dead Sea salt and at least one synthetic, semi-synthetic or natural cannabinoid, a precursor, a derivative, or any combination thereof, or an extract of a cannabis plant.

A method and system in accordance with the subject invention establishes industry norms for every step in the production, cultivation, harvest, and packaging process for a regulated industry to follow with respect to a regulated product. An embodiment relates to the regulated product cannabis where product is accurately recorded into the system is legal while any product that is not recorded into the system is illegal.

A heating device with VPD control for indoor residential cannabis cultivation includes a control module with a processing unit, a display screen and an IO interface; a heater for providing heat and a fan for circulating heat in response to a control signal from the control module; and a temperature-humidity sensor for sensing an environmental temperature value T and an environmental relative humidity value RH within an indoor cannabis cultivation environment. The environmental temperature value T and the environmental relative humidity value RH are transmitted to the control module in real time, and a VPD value is calculated from the environmental temperature value T and the environmental relative humidity value RH by the processing unit of the control module. The VPD value is compared with a pre-determined VPD threshold value to determine running modes of the heater and the fan to control the VPD within the indoor cannabis cultivation environment.

Provided herein are methods of treating cannabinoid intoxication. Further provided herein are metrics for evaluation Cannabis intoxication and the amelioration thereof.

Microemulsion beverages are described where hydrophobic liquid droplets are distributed in a continuous hydrophilic liquid phase. The described microemulsion beverages may be thought of as modified oil-in-water (MOIHW) microemulsions, where both the “oil” and “water” phases of the microemulsion are modified. The oil phase droplets of the MOIHW microemulsion are modified with alcohol and can solubilize oil-soluble species, including cannabis extracts. The polar continuous “water” phase of the MOIHW microemulsion is modified with a sugar or sugar alcohol.

The invention relates to a medicine with drug rehabilitation and relapse prevention effects as well as a preparation method and application thereof, and belongs to the field of medicines. The medicine comprises rotundine and salts and is prepared through a chemical synthesis method, and experiments prove that the medicine preparation has the effects of treating opioid substances including heroin, morphine, dolantin, methadone and the like as well as other psychoactive substances, such as opioid and the like. Independent or addiction formed by cocaine, amphetamine stimulants, wine, smoke, cannabis sativa, sedative and hypnotic drugs and the like has the effects of detoxifying, relieving symptoms, inhibiting psychological craving and reducing relapse rate.